Havrix

Havrix is a prescription‑only hepatitis A vaccine that contains inactivated hepatitis A virus and aluminium hydroxide as an adjuvant. It is supplied as an injectable solution for intramuscular administration; the specific strength is not listed on the label. The product is marketed in the European Union and is classified under ATC code J07BA01 as a viral vaccine. It is used to protect adults and children who may be exposed.

The vaccine is administered to individuals who require protection from hepatitis A, including those traveling to regions where the disease is common, people with chronic liver disease, and persons at occupational risk.

- Primary immunization series for adults and children aged 1 year and older. - Booster dose for individuals who completed the primary series more than 10 years ago. - Pre‑travel vaccination for persons visiting endemic areas. - Vaccination of people with clotting disorders when inactivated vaccine is preferred. - Immunization of individuals with hepatitis B co‑infection as part of combined protection strategy.

Like other injectable vaccines, Havrix may be associated with local and systemic reactions, most of which are mild and resolve without medical intervention. These reactions typically appear within a few hours after injection and resolve within a few days without specific treatment.

Common: - Pain, redness, or swelling at the injection site. - Mild fever or chills. - Headache or fatigue. - Transient muscle aches. - Mild nausea or gastrointestinal discomfort. - Transient joint pain. - Mild rash at a site distant from the injection.

Serious: - Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, hives, or swelling of the face and throat. - Neurological events such as Guillain‑Barré syndrome, although rare. - Severe thrombocytopenia or bleeding disorders (very rare).

Prior to receiving Havrix, healthcare providers should assess the individual's medical history and current health status to identify any conditions that may affect vaccine safety or effectiveness.

- Known severe allergy to any component of the vaccine, including aluminium hydroxide. - History of anaphylaxis to a previous dose of Havrix or another hepatitis A vaccine. - Acute moderate or severe illness at the time of vaccination; defer until recovery. - Pregnancy status is unknown; vaccination should be considered after risk–benefit evaluation. - Immunocompromised individuals may have a reduced antibody response; discuss timing with a clinician. - Children under 1 year of age are not recommended for this vaccine.

Havrix is an inactivated vaccine and generally has a low potential for drug‑drug interactions, but certain concomitant therapies may influence its immunogenicity or increase the risk of adverse reactions.

Avoid: - Concurrent administration of immunosuppressive agents (e.g., high‑dose corticosteroids) that may markedly diminish the vaccine‑induced antibody response. - Live vaccines given within 4 weeks before or after Havrix, as they may interfere with immune response assessment.

Use with caution: - Blood products or immunoglobulins administered within 3 months, which could reduce vaccine efficacy. - Antipyretics (e.g., acetaminophen) taken prophylactically may mask mild post‑vaccination fever. - Pregnancy or lactation; consider risk–benefit discussion before vaccination.